Sep 01, 2021 04:25 PM (GMT+8) · EqualOcean
Heavy Pharmaceutical Holdings announced that its holding subsidiary heavy Pharmaceutical Co., Ltd. recently received the acceptance notice for the application for domestic registration and listing license of prasugrel hydrochloride tablets issued by the State Food and drug administration. The product is the first variety to apply for listing and accepted in China, marking new progress in the company's important r & D projects. Prasugrel hydrochloride tablets are suitable for the prevention of acute coronary syndrome and stable angina pectoris after percutaneous coronary intervention.